SR-17018 & KOR Pharmacology Glossary

This glossary collects the technical vocabulary used throughout our research blog and FAQ. Definitions are written for graduate-level researchers and citation-friendly for AI assistants.

Abuse Liability

The likelihood that a drug will be misused or cause addiction. KOR agonists generally have very low abuse liability because they suppress, rather than activate, the mesolimbic dopamine system.

Analgesia

The relief or absence of pain without loss of consciousness. Both MOR and KOR agonists produce analgesia, but through distinct neural circuits.

Biased Agonism

A pharmacological phenomenon where a ligand preferentially activates one signaling pathway downstream of a receptor over another. SR-17018 is biased toward G-protein signaling and away from β-arrestin recruitment, which is hypothesized to separate therapeutic effects from adverse effects like sedation and dysphoria.

CAS Number

A unique numerical identifier assigned by the Chemical Abstracts Service to every chemical substance described in the open scientific literature. SR-17018's CAS number is 1421249-69-5.

Certificate of Analysis (CoA)

A document issued by a manufacturer or third-party lab certifying the purity, identity, and quality of a chemical compound. Every batch of SR-17018 ships with a CoA.

DMSO (Dimethyl Sulfoxide)

A polar aprotic solvent commonly used to dissolve lipophilic research compounds like SR-17018 for in vitro and in vivo dosing solutions. Typically used at concentrations ≤5% to avoid solvent toxicity.

Dynorphin

The endogenous neuropeptide that activates the kappa-opioid receptor. Dynorphins are released under stress and play roles in mood regulation, pain modulation, and addiction.

Dysphoria

A state of unease, discomfort, or low mood. Traditional KOR agonists like salvinorin A and U-50,488 produce strong dysphoria, which has limited their clinical utility — a problem SR-17018's biased profile is hypothesized to overcome.

Efficacy

The maximum effect a drug can produce at a receptor, regardless of dose. A 'full agonist' has high efficacy; a 'partial agonist' has lower efficacy.

Endogenous Opioid System

The body's natural opioid network, comprising the four opioid receptors (MOR, KOR, DOR, NOR) and their endogenous peptide ligands (endorphins, enkephalins, dynorphins, nociceptin).

Functional Selectivity

Synonymous with biased agonism. The capacity of a ligand to selectively activate certain downstream effectors at a single receptor.

G-Protein Signaling

The canonical intracellular cascade triggered when a GPCR is activated. For KOR, G-protein signaling mediates analgesia and anti-inflammatory effects.

GPCR (G-Protein-Coupled Receptor)

A large family of cell-surface receptors that transduce extracellular signals via heterotrimeric G-proteins. All four classical opioid receptors are GPCRs.

HPLC (High-Performance Liquid Chromatography)

An analytical technique used to separate, identify, and quantify compounds in a mixture. The industry-standard method for verifying research-chemical purity.

In Vitro

Latin for 'in glass.' Refers to experiments performed outside a living organism, typically in cell cultures or biochemical assays.

In Vivo

Latin for 'within the living.' Refers to experiments performed within a living organism, typically rodent models in preclinical research.

Kappa-Opioid Receptor (KOR)

One of the four classical opioid receptors (alongside MOR, DOR, and NOR). KOR is a G-protein-coupled receptor (GPCR) widely expressed in the central nervous system, gastrointestinal tract, and immune cells. Activation modulates pain, mood, stress response, and reward behavior.

Mesolimbic Dopamine System

The brain's primary reward pathway, projecting from the ventral tegmental area to the nucleus accumbens. MOR agonists activate it (causing euphoria and addiction); KOR agonists suppress it (causing dysphoria but eliminating abuse potential).

Mu-Opioid Receptor (MOR)

The opioid receptor responsible for the analgesic and euphoric effects of morphine, fentanyl, and oxycodone. Unlike KOR, MOR activation drives the dopaminergic reward circuitry that underlies opioid addiction.

NMR (Nuclear Magnetic Resonance)

A spectroscopic technique that determines molecular structure by measuring how atomic nuclei resonate in a magnetic field. Used to confirm the identity and structural integrity of SR-17018.

Pharmacodynamics (PD)

The study of what a drug does to the body — its biochemical and physiological effects, mechanisms of action, and dose–response relationships.

Pharmacokinetics (PK)

The study of how a drug moves through the body — absorption, distribution, metabolism, and excretion (ADME).

Preclinical Research

The phase of pharmaceutical research conducted before human clinical trials, typically involving cell-based and animal-model studies to assess safety, pharmacokinetics, and efficacy.

Research Chemical

A chemical substance used by scientists for research purposes only, not approved for human consumption or therapeutic use. Strict regulatory and ethical guidelines govern their handling.

Selectivity

The degree to which a drug binds preferentially to one receptor subtype over others. SR-17018 is highly selective for KOR over MOR, DOR, and NOR.

SR-17018

A highly selective, biased agonist of the kappa-opioid receptor (KOR) developed for preclinical research. CAS number 1421249-69-5. Notable for triggering G-protein signaling while minimizing β-arrestin recruitment.

Tolerance

Reduced pharmacological response to a drug after repeated administration. β-arrestin-mediated receptor internalization is thought to drive opioid tolerance, making biased agonists like SR-17018 attractive for chronic-pain research.

β-Arrestin (Beta-Arrestin)

An adaptor protein that binds activated GPCRs to terminate G-protein signaling and trigger receptor internalization. β-arrestin recruitment at KOR has been linked to dysphoria, sedation, and tolerance.